

## Special Issue

# Immune Response against SARS-CoV-2

### Message from the Guest Editor

This special issue seeks all types of manuscripts (e.g., reviews, research articles, and short communications) on the immune response in individuals infected or vaccinated against SARS-CoV-2. Both basic and applied research papers that aim to improve the understanding of the immune response against SARS-CoV-2, short- and long-term effects of host immune responses to SARS-CoV-2, improved diagnostic methods, vaccination-related immune response, and intervention strategies for the prevention and management of COVID-19-related autoimmune reactions are welcome. We cordially invite you to contribute to this special issue to advance our knowledge of SARS-CoV-2 and to discover together the means to overcome the pandemic. I look forward to receiving your contributions.

### Guest Editor

Dr. Angela Stufano

DIM Section of Occupational Medicine "EC Vigliani", Università degli studi di Bari Aldo Moro, 70121 Bari, Italy

### Deadline for manuscript submissions

closed (31 January 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/104950](https://mdpi.com/si/104950)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).